Wirtz_2010_Expert.Rev.Clin.Immunol_6_867

Reference

Title : 3,4-diaminopyridine for the treatment of Lambert-Eaton myasthenic syndrome - Wirtz_2010_Expert.Rev.Clin.Immunol_6_867
Author(s) : Wirtz PW , Titulaer MJ , Gerven JM , Verschuuren JJ
Ref : Expert Rev Clin Immunol , 6 :867 , 2010
Abstract :

The Lambert-Eaton myasthenic syndrome (LEMS) is an autoimmune disease in which antibodies against voltage-gated calcium channels inhibit cholinergic neurotransmission. LEMS is clinically characterized by muscle weakness and autonomic dysfunction. 3,4-diaminopyridine (3,4-DAP) blocks potassium channels in nerve terminals, resulting in an increase in acetylcholine release. This article describes the four randomized placebo-controlled trials of 3,4-DAP in patients with LEMS. All trials demonstrated a significant effect on muscle strength and compound muscle action potential amplitude. Furthermore, the safety and tolerability of 3,4-DAP are reviewed. The side effects of 3,4-DAP are generally mild and most frequently consist of paresthesias, but epileptic seizures and arrhythmias have been described in patients using high doses. Given the efficacy and safety of 3,4-DAP in LEMS, this drug is the mainstay for symptomatic treatment of LEMS.

PubMedSearch : Wirtz_2010_Expert.Rev.Clin.Immunol_6_867
PubMedID: 20979551

Related information

Citations formats

Wirtz PW, Titulaer MJ, Gerven JM, Verschuuren JJ (2010)
3,4-diaminopyridine for the treatment of Lambert-Eaton myasthenic syndrome
Expert Rev Clin Immunol 6 :867

Wirtz PW, Titulaer MJ, Gerven JM, Verschuuren JJ (2010)
Expert Rev Clin Immunol 6 :867